Clinical trial · Observational
Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases
Whole Body MRI for Detection of Cancer Metastases
NCT00592462CI-TRIAL-00024483completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this pilot study is to develop and evaluate a whole body MRI technique for detecting cancer metastases. The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole Body MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Whole Body MRI
- interventionNames
- Procedure: Whole Body MRI
Primary outcomes (1)
- measure
- Develop and evaluate a whole body MRI technique for detecting cancer metastases.
- timeFrame
- 3 Years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Breast cancer patients with high suspicion or confirmed bone metastases. 2. Patient who have undergone a clinically indicated skeletal scintigraphy within two weeks of the MRI exam. 3. Patients who have signed their informed consent form to undergo the study. Exclusion Criteria: 1\) Contraindication to conventional MR imaging (e.g. metal implants, pace maker, etc.).
References
Publications (0)
Data not yet available
No reference posted for this study.